Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)

Contributed by: Business Wire

Logo

Tags

Science

Other Science

Biotechnology

Research

General Health

Health

FDA

Clinical Trials

Alzprotect

More Like This

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens

Ferrer's pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain.

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial

Ferrer's pharmaceutical production plant in Sant Cugat del Vallés, Barcelona, Spain.

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

PR Newswire associated0

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

PR Newswire associated0

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant

FDA Clears Abionic’s IVD CAPSULE PSP for the Early Detection of Sepsis